Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
monster number sitting at the ask. Ugh.
More than one approval track. Don't wait too long.
Two big 1 million share buy blocks today.
I bet we get news next week.
Thanks for sharing. I will check it out. I don't day trade but I always am interesting in learning new things.
Now, the Fibonacci Retracement? That sounds like something Deuce Bigolow and his man-ho's offer.
I assume charts work best in the absence of news? How does news affect these charts? (Good news, that is). People are saying they could see this a few weeks ago. If so, pretty impressive. And can someone teach me, lol.
Agreed. If they had any type of tangible news about deals that might bring in revenue, that could make this ugly beast pop with such a small float. 17 mill is peanuts...unless Fong is busy dumping as I type, lol.
HAHA! No doubt!
Someone is dumping some blocks...Wish I had the coin to snatch 'em up, lol.
Nice pull! Thank you for sharing.
This company only has 17 million shares outstanding? or am I wrong on that point? If so, seems like it might move if there is solid news. IF.
Good luck all. This is going to end well.
Getting antsy Econ? lol.
Wait, why am I even bothering to respond? I'm not going to waste any more of my time for sure.
Good luck all.
http://www.epaccontrol.com/common/sitemedia/PrePost/PostPDFs/1035588.pdf
When you were growing up, did you think this would be your job? LOL. Stop embarrassing yourself.
Somewhere in a dimly lit room sits Simon Wagstaff, Benedict Cumberpatch, Godric Gryffindor and Salar Slythrin plotting to walk down OXIS.
Thanks for the laugh.
Oh, and Econ Student? "Fetch boy!"
Ah Exon student arrives! Excellent. A move north is coming. Lol. Too predictable.
Shortly before each spike, a troll appears to talk it down. It doesn't work.
But your arrival signals the beginning of a move north, so welcome!
Read the most recent filings to better educate yourself, re:$500k. It's embarrassing.
I didn't mean to speak for other folks on this message board. My apologies.
Bud bounced when this puppy hit almost $.06. I suspect he did well, and good for him.
And if he is still holding some, even better for him.
Me neither. I saw it last night--but I found it only within the investorhub website and assumed he was already part of the SAB or it was old information.
Cataldo is either a lunatic or a biotech genius. If--and at this point it's a HUGE if--the drug therapies prove sound, it's going to be one hell of a ride.
At $.04 a share, why not buy a ticket to the show?
I bought into this black hole based on my own crappy due diligence earlier this year. I thought these jokers were going to be the mortgage processors for Netlife Financial. However, buried in their recent 10K turns out they are not. Fong would have been a golden god. Instead? This turd will pop from time to time, people will make carnival money, and life will go on.
The Chong card? Eyes rolling. This guy is slapping his name on any weed-related garbage--when he isn't high, which if you read his Twitter feed, isn't very often.
This whole operation? Clown college.
I plan on nuking this garbage the minute I am within 15% of breaking even.
Ending on a positive note in Europe today. Let's hope it carries over to the States.
Thanks for posting. I will revisit.
Was also curious about whether OXIS has a significant nexus to the "European Economic Area" to be classified a SME (Small and Medium Sized Enterprise) for purposes of Step I and Step II of the Adaptive Pathways Project. Trying to reverse engineer via Edgar filings and the European Medicines Agency literature.
That said, I've done enough analysis, ***REDACTED*** text aside, to feel comfortable with my investment.
Until additional news comes out, I'm going to sit back, watch and wait. Hoping OXIS does some pretty incredible things--chief among them easing the suffering of people inflicted with this scourge. Thereafter, everything else will fall in place.
Give 'em hell OXIS
Interesting website. http://www.ema.europa.eu/ema/
fingers crossed for 2015.
OXIS has the drug compound candidates, MCIT has the molecule delivery vehicle, and that research agreement hints at another entity being involved in the developed results...I agree, who we missing?
---
Here are my guesses:
1. Employees of a regulatory agency (US or EU);
2. A big pharma manufacturer specializing in ADC (Anti-body Drug Conjugates) production. After all, somebody will need to make sufficient quantities of the secret sauce to bring to market. Presently, neither OXIS or MCIT have that capability (to my knowledge);
3. Perhaps a 'strategic partner' Cataldo mentioned in his 2-25 letter to shareholders; or
4. #2 & #3 one in the same?
In my opinion, it looks as if all the ducks have been lined up.
Now, of course, comes the $64,000 question...will the drug(s) show enough promise to advance to clinical trials?
I have to believe the answer to that question will come at some point in 2015.
Good luck all.
Very, very clever, OXIS.
Spent yesterday reading the Reasearch and License Agreements. They are well constructed, imo. There are a number of potentially interesting nuggets to help connect the dots. But since I admit up front I am wearing rose colored glasses when it comes to OXIS, I'll keep them to myself.
There are also some stinker aspects to the stock (something is going to need to be done about authorized shares vs. outstanding shares).
Either way, I will continue to add to my position. At $.04, OXIS is certainly worth the price of admission.
any disclosure by OXIS of Confidential Information related to the Developed Result, including any Project Information, whether electronic, written or oral, to any third party including but not limited to consultants, agents, independent contractors, investors, or business partners is prohibited, except that OXIS is permitted to disclose portions of Confidential Information related to the Developed Result to employees of ***[REDACTED]***
Wonder who this might be...
I would probably make a call to my broker. But that's just me.
By the 9.9 ownership, there are 17.4M shares.
Well this is interesting. Anyone know anything about Carebourn Capital, L.P.? They now own 9.9% of FFFC.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
FastFunds Financial Corporation
(Name of Issuer)
Common Stock
(Title of Class of Securities)
31188E108
(CUSIP Number)
Carebourn Capital, L.P.
8700 Blackoaks Lane North
Maple Grove, MN 55311
612-889-2418
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
March 6, 2015
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 31188E108 13G Page 2 of 5 Pages
1.
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Carebourn Capital, L.P.
EIN #26-4658563
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) [ ]
(b) [ ]
3. SEC USE ONLY
4. CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America, State of Minnesota
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH 5. SOLE VOTING POWER
1,723,138
6. SHARED VOTING POWER
0
7. SOLE DISPOSITIVE POWER
1,723,138
8. SHARED DISPOSITIVE POWER
0
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,723,138
10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ]
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.9%
12. TYPE OF REPORTING PERSON (see instructions)
Accredited Investor
In the grand scheme of the possibility of this stock, a penny is a pittance.
Mark my words...Fong is an absolute FOOL for letting NetLife Financial mortgage processing slip through his hands. What an absolute idiot. Makes me wonder just how high he really is...
Tons of reasons. All their clinical trials could be flops. But for price point entry in biotech sector, this provides very high reward. A lot of ifs, but the potential is there, truly.
You never know but I doubt it. Base has been building and this stock is, imho, only going north. Now, there will be consolidation after news moves the stock, but I don't day trade so that's of no interest to me.
LOL. I completely agree. Totally baffled by this. I guess if you don't understand it, you don't understand it. Thanks for the buying oppt.
Sorry if this has already been posted. January article on Oxis from SeekingAlpha:
Oxis International, Inc. (OTCPK:OXIS) (OXI.PA) through its subsidiary, Oxis Biotech, Inc. has recently come into the space as well. It appears that following the company becoming current with its filings as well as releasing two very prominent pieces of press, activity in the stock has increased with January 14 seeing the highest volume day in the stock. Over the last 30 days, Oxis shares also have seen highs of $0.039 even with the caveat status on OTC Markets. This was an obvious trigger to take a closer look as seemingly, "something's up".
Over recent weeks, the company has made two announcements that put this on the list of possible cannabis investments in 2015 and both are material in nature. Further diligence shows that not only has Oxis executed definitive agreements licensing certain assets for the treatment of multiple myeloma but the company has also brought on one of the foremost authorities in CBD research especially those diagnosed with multiple myeloma, breast cancer, and even research in the stem cell arena, Dr. Sean Xie (Dr. Xiangqun Xie). According to the website cbdligand.org, "Xie's research work is beyond the proof-of-principle stage since his group has already successfully identified several novel CB2 ligands with nanomolar receptor binding affinity (US patents). The methods and results developed will have a significant impact on the other GPCRs drug research in general. Currently, he has established collaboration with MD experts in University of Pittsburgh Medical Center for in vivo animal evaluation."
In addition to this, the Company also announced that Dr. James J. Mulé, Ph.D. who is a Special Government Employee of the NCI and the FDA, joins that company's Scientific Advisory Board. Among many of his accomplishments, Dr. Mulé is recognized for his translational research studies in cancer immunotherapy. Mulé previously worked with Oxis CEO Tony Cataldo when Mr. Cataldo previously formed Genesis Biopharma (previous GNBP) which later became Lion Biotechnologies. Under the helm of Mr. Cataldo, Genesis came from a penny stock and built enough shareholder value to increase to $8+ per share.
As far as paid in capital is concerned, Oxis shows more of a vested interest along the lines of a company like Insys as opposed to one like PEAK. Therefore it could be very possible that the CEO who took Genesis to "the next level" may have found another company to build as OXIS has continued to gain more investor interest this past week. Despite these achievements and increased market liquidity, the obvious risks unassociated with the small market cap, lower share price, and volatility will also include the fact that Oxis will still need to put in place a plan or outline for what the company will focus on specifically. A strong team to conduct R&D is a good start but as the company has just become fully reporting, the need for more company developments regarding production is needed in my opinion.
As noted in several instances, I've mentioned paid in capital in this article for the simple fact that many biotechs generally are pre-revenue through the multiple stages of R & D and phases of FDA approval. This valuation method has been used because when you're not selling product, how can success be determined? By utilizing "paid-in-capital" valuations, investors can clearly see that amount of capital available to fund a biotech company's research.
Investing in cannabis companies in the US at this point remains highly speculative and obvious risks reach far beyond simple market volatility. As far as biotechs go, drugs not passing FDA approval or even reacting negatively during the trial periods can put a huge barrier up for a company. For the cannabis industry as a whole (even though it doesn't necessarily effect biotechs) federal regulation can change at any point and time so just as the government made certain aspects legal, they can easily overturn those to make them illegal. The main point is that by investing in reputable companies focused on biotech may produce significant returns in the current climate as many states have not legalized the drug for over the counter sale.
The real investment right now I feel is in the biotech side of the space. For one, as far as regulatory issues are concerned, these companies do not face the same state-by-state restrictions that many typical marijuana based businesses face. Much of the studies are funded by government-sponsored funds and thus would have to meet the criteria of organizations like the FDA. This makes biotech a great candidate through 2016, which is when the next elections are planned & potential legalization votes go back on the ballot. Second, the biotech space is growing at an annual rate of 11% (market revenue is just under $300B according to IBISWorld). Finally, The Arcview Group forecasts that the legal marijuana industry will increase to $10 billion in 2019, so there is obvious opportunity within the industry just as it is beginning to grow. As history has proven with growth driven industries, the first-movers who take an early foothold manage to gain the largest market share. What companies like Google and Apple have done for tech, cannabis biotechs like those mentioned can do it for the marijuana industry.
OXIS did well in Europe today.